

## Supplementary Materials

### Titles

**Table S1.** Distribution of the urinary volatile organic compounds (VOCs) levels in NHANES 2011-2016 (n = 29902).

**Table S2.** All detailed coefficients of WQS model.

**Table S3.** Posterior inclusion probabilities (PIPs) of all BKMR model.

**Table S4.** The total and direct effects of urinary volatile organic compounds (VOCs) on Klotho in general population.

**Table S5.** The mediation effect of urinary volatile organic compounds (VOCs) on Klotho with TB, ALT, AST and GGT in general population.

**Figure S1.** Flow chart of participants selection.

**Figure S2.** Correlation between urinary volatile organic compounds (VOCs).

**Figure S3.** WQS model regression index weights with different population.

**Figure S4.** The bivariate exposure-response function for two urinary volatile organic compounds (VOCs).

**Figure S5.** Single-variable effect in general population (40-79 years) by BKMR models.

**Figure S6.** Single-variable effect in elderly population (60-79 years) by BKMR models.

**Figure S7.** Single-variable effect in middle age population (40-59 years) by BKMR models.

**Table S1.** Distribution of the urinary urinary volatile organic compounds (VOCs) levels in NHANES 2011-2016 (n = 29902).

Variable	LLOD	10 <sup>th</sup> percentile	25 <sup>th</sup> percentile	50 <sup>th</sup> percentile	75 <sup>th</sup> percentile	90 <sup>th</sup> percentile
<b>2MHA</b>	5.000	2733.009	4552.665	6372.301	8191.947	10011.593
<b>3MHA+4MHA</b>	8.000	8254.811	13754.245	19253.679	24753.113	30252.547
<b>AAMA</b>	2.200	469.326	781.170	1093.014	1404.858	1716.702
<b>AMCC</b>	6.260	651.765	1083.322	1514.880	1946.436	2377.993
<b>ATCA</b>	15.00	372.010	612.950	853.890	1094.830	1335.770
<b>BMA</b>	0.500	199.801	332.765	465.730	598.695	731.659
<b>BPMA</b>	1.200	109.772	182.387	255.002	327.618	400.232
<b>CEMA</b>	6.960	734.682	1221.19	1707.698	2194.206	2680.714
<b>CYMA</b>	0.500	246.301	410.265	574.23	738.195	902.159
<b>DHBMA</b>	5.250	495.154	822.783	1150.412	1478.041	1805.670
<b>DPMA</b>	0.500	1.258	1.860	2.463	3.066	3.668
<b>GAMA</b>	9.400	73.903	118.737	163.573	208.408	253.242
<b>HEMA</b>	0.791	11.245	18.369	25.493	32.617	39.742
<b>2GPMA</b>	5.300	1477.688	2460.312	3442.938	4425.562	5408.188
<b>3HPMA</b>	13.000	4117.82	6856.900	9595.980	12335.06	15074.140
<b>MA</b>	12.000	4132.225	6881.375	9630.525	12379.675	15128.825
<b>MHBMA1</b>	0.700	0.754	0.926	1.099	1.271	1.444
<b>MHBMA1</b>	0.700	14.656	24.096	33.537	42.977	52.418
<b>MHBMA3</b>	0.700	61.41	102.068	142.726	183.383	224.041
<b>PHEMA</b>	0.700	82.921	137.871	192.822	247.772	302.723
<b>PGA</b>	0.700	4837.225	8056.375	11275.525	14494.675	17713.825
<b>PMA</b>	0.600	4.605	7.393	10.181	12.968	15.756
<b>HPMMA</b>	1.700	2131.020	3550.900	4970.780	6390.660	7810.540

VOCs, Volatile organic compounds. The variable names are detailed in the attached table.

**Table S2.** All detailed coefficients of WQS model.

Coefficients of WQS model with negative beta (elderly population)					Coefficients of WQS model with positive beta (elderly population)				
	Estimate	Std.Error	t-value	Pr(> t )		Estimate	Std.Error	t-value	Pr(> t )
(Intercept)	900.0715	179.5508	5.013	7.71e-07***	(Intercept)	890.0127	178.4074	4.989	8.69e-07***
<b>wqs</b>	<b>4.5868</b>	<b>15.8905</b>	<b>0.289</b>	<b>0.773</b>	<b>wqs</b>	<b>30.5502</b>	<b>15.6238</b>	<b>1.955</b>	<b>0.0512</b>
<b>Gender</b>	16.9741	27.5999	0.615	0.5389	<b>Gender</b>	12.484	27.4338	0.455	0.6493
<b>Age</b>	-0.414	2.2407	-0.185	0.8535	<b>Age</b>	-0.546	2.2325	-0.245	0.8069
<b>Race/Ethnicity</b>	6.2908	12.7499	0.493	0.622	<b>Race/Ethnicity</b>	4.9033	12.6927	0.386	0.6994
<b>Education level</b>	8.1399	14.922	0.545	0.5857	<b>Education level</b>	8.7694	14.8619	0.59	0.5554
<b>BMI</b>	0.1213	2.0753	0.058	0.9534	<b>BMI</b>	-0.2823	2.0641	-0.137	0.8913
<b>Diabetes</b>	-23.2139	28.9328	-0.802	0.4228	<b>Diabetes</b>	-24.0756	28.7898	-0.836	0.4035
<b>Hypertension</b>	16.9359	26.2613	0.645	0.5193	<b>Hypertension</b>	20.2994	26.2045	0.775	0.439
<b>Cigarette smoking</b>	-35.6478	26.5239	-1.344	0.1796	<b>Cigarette smoking</b>	-43.0027	26.3328	-1.633	0.1032
<b>Alcohol drinking</b>	-45.9097	28.4529	-1.614	0.1073	<b>Alcohol drinking</b>	-49.7497	28.3698	-1.754	0.0802
<b>Creatinine</b>	-0.8771	0.4674	-1.877	0.0612	<b>Creatinine</b>	-0.808	0.4666	-1.732	0.084

Coefficients of WQS model with negative beta (middle age population)					Coefficients of WQS model with positive beta (middle age population)				
	Estimate	Std.Error	t-value	Pr(> t )		Estimate	Std.Error	t-value	Pr(> t )
(Intercept)	1198.684	166.7394	7.189	2.22e-12***	(Intercept)	1143.703	168.2139	6.799	2.84e-11***
<b>wqs</b>	-48.7976	17.7134	-2.755	0.00607**	<b>wqs</b>	-14.6113	17.0513	-0.857	0.3919
<b>Gender</b>	62.595	30.3243	2.064	0.03948*	<b>Gender</b>	61.3949	30.7081	1.999	0.0461*
<b>Age</b>	-6.3411	2.5065	-2.53	0.01170*	<b>Age</b>	-5.7584	2.5153	-2.289	0.0225*
<b>Race/Ethnicity</b>	18.9473	15.0063	1.263	0.20728	<b>Race/Ethnicity</b>	16.2025	15.0821	1.074	0.2832
<b>Education level</b>	-4.3297	19.4676	-0.222	0.82408	<b>Education level</b>	0.1895	19.5239	0.01	0.9923

<b>BMI</b>	-0.4238	2.0697	-0.205	0.83785
<b>Diabetes</b>	-8.4067	42.0902	-0.2	0.84177
<b>Hypertension</b>	-29.4544	31.785	-0.927	0.35452
<b>Cigarette smoking</b>	62.756	31.9414	1.965	0.04997 *

<b>BMI</b>	-0.9113	2.0748	-0.439	0.6607
<b>Diabetes</b>	-8.4524	42.365	-0.2	0.8419
<b>Hypertension</b>	-28.8083	31.9897	-0.901	0.3682
<b>Cigarette smoking</b>	38.9309	31.0951	1.252	0.2111

**Coefficients of WQS model with negative beta (general population)**

**Coefficients of WQS model with positive beta (general population)**

	Estimate	Std.Error	tvalue	Pr(> t )
(Intercept)	1016.2567	103.6113	9.808	< 2e-16***
<b>wqs</b>	-29.555	13.2675	-2.228	0.02613*
<b>Gender</b>	44.9184	22.3526	2.01	0.04475*
<b>Age</b>	-2.0725	1.0251	-2.022	0.04346*
<b>Race/Ethnicity</b>	28.6345	10.8211	2.646	0.00827**
<b>Education level</b>	-7.9556	13.1244	-0.606	0.54454
<b>BMI</b>	-0.8979	1.6152	-0.556	0.57842
<b>Diabetes</b>	-42.8391	26.6688	-1.606	0.10852
<b>Hypertension</b>	-5.2894	21.9303	-0.241	0.80945
<b>Cigarette smoking</b>	22.503	22.5852	0.996	0.31932

	Estimate	Std.Error	t-value	Pr(> t )
(Intercept)	979.3043	102.9162	9.516	<2e-16***
<b>wqs</b>	-16.0885	12.6015	-1.277	0.202
<b>Gender</b>	49.5841	23.2172	2.136	0.0330*
<b>Age</b>	-2.0597	1.0282	-2.003	0.0454*
<b>Race/Ethnicity</b>	26.4092	10.8539	2.433	0.0151*
<b>Education level</b>	-1.938	13.2711	-0.146	0.8839
<b>BMI</b>	-0.3392	1.5697	-0.216	0.829
<b>Diabetes</b>	-61.6946	26.4465	-2.333	0.0199*
<b>Hypertension</b>	13.1034	22.1501	0.592	0.5543
<b>Cigarette smoking</b>	18.5302	21.9175	0.845	0.3981

\*, P < 0.05; \*\*, P < 0.01; \*\*\*, P < 0.001.

**Table S3.** Posterior inclusion probabilities (PIPs) of all BKMR model.

	General	40-59 years	60-79 years
2MHA	0.0040	0.3478	0.0000
3MHA+4MHA	0.0000	0.4012	0.0000
AAMA	0.0012	0.3972	0.0000
AMCC	0.0642	0.4746	0.0202
ATCA	0.0044	0.3962	0.5652
BMA	0.0000	0.4190	0.0000
BPMA	0.0000	0.4204	0.0140
CEMA	0.0106	0.4910	0.0072
CYMA	0.0000	0.4454	0.0092
DHBMA	0.0000	0.5288	0.0000
2HPMA	0.0060	0.4796	0.0200
3HPMA	0.0224	0.4102	0.0218
MA	0.0000	0.4504	0.0154
MHBMA3	0.0436	0.4454	0.0762
PGA	0.0170	0.4408	0.0384
HPMMA	0.0166	0.4184	0.0030

2MHA, Urinary 2-Methylhippuric acid; 3MHA+4MHA, Urinary 3- and 4-Methylhippuric acid; AAMA, Urinary N-Acetyl-S-(2-carbamoylethyl)-L-cysteine; AMCC, Urinary N-Acetyl-S-(N-methylcarbamoyl)-L-cysteine; ATCA, Urinary 2-Aminothiazoline-4-carboxylic acid; BMA, Urinary N-Acetyl-S-(benzyl)-L-cysteine; BPMA, Urinary N-Acetyl-S-(n-propyl)-L-cysteine; CEMA, Urinary N-Acetyl-S-(2-carboxyethyl)-L-cysteine; CYMA, Urinary N-Acetyl-S-(2-cyanoethyl)-L-cysteine; DHBMA, Urinary N-Acetyl-S-(3,4-dihydroxybutyl)-L-cysteine; 2HPMA, Urinary N-Acetyl-S-(2-hydroxypropyl)-L-cysteine; 3HPMA, Urinary N-Acetyl-S-(3-hydroxypropyl)-L-cysteine; MA, Urinary Mandelic acid; MHBMA3, Urinary N-Acetyl-S-(4-hydroxy-2-butenyl)-L-cysteine; PGA, Urinary Phenylglyoxylic acid; HPMMA, Urinary N-Acetyl-S-(3-hydroxypropyl-1-methyl)-L-cysteine.

**Table S4.** The total and direct effects of urinary volatile organic compounds (VOCs) on Klotho in general population.

VOCs	Total effect (Mean±SE, <i>P</i> value)	Direct effect (95%CI)
2MHA	0.014±0.083, ns	0.026 (-0.183, 0.198)
3MHA+4MHA	-0.005±0.013, ns	-0.002(-0.029, 0.022)
AAMA	-0.138±0.095, ns	-0.089(-0.254, 0.094)
AMCC	<b>-0.063±0.024, **</b>	<b>-0.047(-0.093, -0.001)</b>
ATCA	-0.074±0.04, ns	-0.045 (-0.116, 0.026)
BMA	-0.039±0.281, ns	-0.154(-0.672, 0.286)
BPMA	-0.129±0.283, ns	-0.029(-0.433, 0.507)
CEMA	<b>-0.099±0.044, *</b>	-0.08(-0.170, 0.011)
CYMA	<b>-0.071±0.03, **</b>	<b>-0.067(-0.123, -0.011)</b>
DHBMA	-0.071±0.058, ns	-0.058(-0.158, 0.044)
2HPMA	<b>-0.027±0.011, ***</b>	-0.021(-0.045, 0.003)
3HPMA	<b>-0.201±0.074, *</b>	<b>-0.174(-0.317, -0.033)</b>
MA	<b>-0.082±0.036, **</b>	<b>-0.07(-0.140, -0.004)</b>
MHBMA3	<b>-0.988±0.382, *</b>	-0.777(-1.541, 0.027)
PGA	<b>-0.086±0.032, **</b>	<b>-0.075(-0.144, -0.022)</b>
HPMMA	<b>-0.022±0.01, ***</b>	-0.018(-0.038, 0.002)
Mixed VOCs	<b>-38.90±9.94, ***</b>	<b>-30.50(-53.271, -8.034)</b>

\*, *P* < 0.05; \*\*, *P* < 0.01; \*\*\*, *P* < 0.001; ns, not significant. 2MHA, Urinary 2-Methylhippuric acid; 3MHA+4MHA, Urinary 3- and 4-Methylhippuric acid; AAMA, Urinary N-Acetyl-S-(2-carbamoyl-ethyl)-L-cysteine; AMCC, Urinary N-Acetyl-S-(N-methylcarbamoyl)-L-cysteine; ATCA, Urinary 2-Aminothiazoline-4-carboxylic acid; BMA, Urinary N-Acetyl-S-(benzyl)-L-cysteine; BPMA, Urinary N-Acetyl-S-(n-propyl)-L-cysteine; CEMA, Urinary N-Acetyl-S-(2-carboxyethyl)-L-cysteine; CYMA, Urinary N-Acetyl-S-(2-cyanoethyl)-L-cysteine; DHBMA, Urinary N-Acetyl-S-(3,4-dihydroxybutyl)-L-cysteine; 2HPMA, Urinary N-Acetyl-S-(2-hydroxypropyl)-L-cysteine; 3HPMA, Urinary N-Acetyl-S-(3-hydroxypropyl)-L-cysteine; MA, Urinary Mandelic acid; MHBMA3, Urinary N-Acetyl-S-(4-hydroxy-2-butenyl)-L-cysteine; PGA, Urinary Phenylglyoxylic acid; HPMMA, Urinary N-Acetyl-S-(3-hydroxypropyl-1-methyl)-L-cysteine.


**Table S5.** The mediation effect of urinary volatile organic compounds (VOCs) on Klotho with TB, ALT, AST and GGT in general population.

VOCs	Indirect effect (95%CI)			
	TB	ALT	AST	GGT
2MHA	-0.001(-0.015, 0.009)	0.001 (-0.017, 0.016)	-0.008(-0.039, 0.026)	-0.003(-0.015, 0.008)
3MHA+4MHA	0(-0.002, 0.002)	0.001 (-0.001, 0.004)	-0.004(-0.010, 0.000)	-0.001(-0.002, 0.001)
AAMA	<b>-0.018(-0.038, -0.003)</b>	0.036(-0.006, 0.068)	<b>-0.017(-0.135, -0.002)</b>	0.003(-0.008, 0.018)
AMCC	<b>-0.006(-0.011, -0.001)</b>	0.005 (-0.001, 0.011)	-0.015(-0.036, 0.000)	0(-0.003, 0.002)
ATCA	-0.009 (-0.019, -0.002)	0.01(-0.001, 0.021)	-0.033(-0.072, -0.000)	0.002 (-0.003, 0.007)
BMA	0.018(-0.019, 0.082)	-0.104(-0.227, 0.040)	0.207 (-0.085, 0.405)	-0.006 (-0.025, 0.023)
BPMA	-0.027(-0.073, 0.018)	0.023(-0.026, 0.071)	<b>-0.096(-0.190, -0.001)</b>	0 (-0.046, 0.039)
CEMA	<b>-0.009(-0.018, -0.002)</b>	0.011(-0.002, 0.023)	-0.021(-0.052, 0.001)	0(-0.003, 0.004)
CYMA	-0.004(-0.010, 0.001)	0.006(-0.001, 0.016)	-0.005(-0.022, 0.008)	0(-0.003, 0.003)
DHBMA	-0.006(-0.016, 0.003)	0.006 (-0.002, 0.016)	<b>-0.016(-0.033, -0.001)</b>	0.002(-0.003, 0.008)
2HPMA	<b>-0.004(-0.007, -0.001)</b>	<b>0.004 (0.001, 0.007)</b>	<b>-0.006(-0.014, -0.001)</b>	0 (-0.001, 0.001)
3HPMA	<b>-0.015 (-0.032, -0.003)</b>	0.022(-0.003, 0.043)	-0.032(-0.081, 0.004)	-0.002(-0.011, 0.006)
MA	-0.005(-0.016, 0.001)	0.007(-0.001, 0.016)	-0.012(-0.037, 0.003)	-0.001(-0.004, 0.003)
MHBMA3	<b>-0.099(-0.193, -0.024)</b>	0.13(-0.018, 0.253)	-0.242 (-0.541, 0.002)	-0.001(-0.031, 0.036)
PGA	-0.003(-0.010, 0.002)	0.009(-0.001, 0.018)	<b>-0.018(-0.041, -0.000)</b>	0.001(-0.002, 0.005)
HPMMA	<b>-0.002(-0.005, -0.001)</b>	<b>0.003(0.001, 0.005)</b>	-0.004(-0.011, 0.001)	0(-0.001, 0.001)
Mixed VOCs	<b>-2.231(-4.667, -0.425)</b>	1.332(-0.676, 4.370)	-7.453(-21.734, 0.502)	-0.041(-1.063, 1.118)


Estimate value (95% confidence interval). The confidence intervals were calculated using the bootstrap method and significance were denoted using bold font.

2MHA, Urinary 2-Methylhippuric acid; 3MHA+4MHA, Urinary 3- and 4-Methylhippuric acid; AAMA, Urinary N-Acetyl-S-(2-carbamoylethyl)-L-cysteine; AMCC, Urinary N-Acetyl-S-(N-methylcarbamoyl)-L-cysteine; ATCA, Urinary 2-Aminothiazoline-4-carboxylic acid; BMA, Urinary N-Acetyl-S-(benzyl)-L-cysteine; BPMA, Urinary N-Acetyl-S-(n-propyl)-L-cysteine; CEMA, Urinary N-Acetyl-S-(2-carboxyethyl)-L-cysteine; CYMA, Urinary N-Acetyl-S-(2-cyanoethyl)-L-cysteine; DHBMA, Urinary N-Acetyl-S-(3,4-dihydroxybutyl)-L-cysteine; 2HPMA, Urinary N-


Acetyl-S-(2-hydroxypropyl)-L-cysteine; 3HPMA, Urinary N-Acetyl-S-(3-hydroxypropyl)-L-cysteine; MA, Urinary Mandelic acid; MHBMA3, Urinary N-Acetyl-S-(4-hydroxy-2-butenyl)-L-cysteine; PGA, Urinary Phenylglyoxylic acid; HPMMA, Urinary N-Acetyl-S-(3-hydroxypropyl-1-methyl)-L-cysteine.




**Figure S1.** Flow chart of participants selection. NHANES, National Health and Nutrition Examination Survey.




**Figure S2.** The Pearson correlation coefficients among all urinary volatile organic compounds (VOCs). The blank regions indicate a lack of significant correlation among the VOCs.




**Figure S3.** WQS model regression index weights with different population. (A) Positive WQS model regression index weights with middle age population (B) Positive WQS model regression index weights with elderly population. All P value of wqs > 0.05




**Figure S4.** The bivariate exposure-response function for two urinary volatile organic compounds (VOCs). All of the other exposures are fixed at a particular quantile (0.1,0.5,0.9) in middle age population.



**Figure S5.** Single-variable effect (95% credible intervals) of the expos (normalized and centered urine VOCs concentration) on Klotho, where all of the other exposures are fixed to 50th quantile in general population (40-79 years) by BKMR models.



**Figure S6.** Single-variable effect (95% credible intervals) of the expos (normalized and centered urine VOCs concentration) on Klotho, where all of the other exposures are fixed to 50th quantile in elderly population (60-79 years) by BKMR models.



**Figure S7.** Single-variable effect (95% credible intervals) of the expos (normalized and centered urine VOCs concentration) on Klotho, where all of the other exposures are fixed to 50th quantile in middle age population (40-59 years) by BKMR models.